MetaCap

Actuate Therapeutics (ACTU) vs Allarity Therapeutics (ALLR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Allarity Therapeutics (ALLR) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 25.9% versus a loss of 96.4%. Actuate Therapeutics is the larger company by market cap ($13.6 million vs $12.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACTU-96.43%ALLR-25.94%
+75%-15%-105%
Nov 21, 20251 yearNov 20, 2026
ACTU-97.41%ALLR-84.42%
+43%-30%-104%
Aug 12, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACTU versus ALLR key metrics
MetricACTUALLR
Share price$0.2253$0.785
Market cap$13.60M$12.56M
1-day change+5.38%-9.25%
YTD return-96.32%-27.31%
1-year return-96.43%-25.94%
EPS (TTM)$-0.76$-0.79
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$320.00K
Net income (latest FY)$-22.23M$-11.23M
Operating margin—-3939.06%
Net margin—-3509.69%
52-week high$7.90$1.84
52-week low$0.174$0.769
Distance from 52-week high-97.15%-57.34%
Analyst consensusnonenone
Avg. price target upside+5084.20%+1301.27%
Average volume807.24K131.74K
Shares outstanding60.38M16.00M
Employees127
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ALLR has outperformed ACTU by 70.5 percentage points over the past year.

About Actuate Therapeutics

ACTU stock →

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About Allarity Therapeutics

ALLR stock →

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

ACTU vs ALLR FAQ

Which is bigger, Actuate Therapeutics or Allarity Therapeutics?

Actuate Therapeutics (ACTU) is larger, with a market capitalization of $13.60M compared with $12.56M for Allarity Therapeutics (ALLR).

Which stock has performed better over the past year, ACTU or ALLR?

ALLR returned -25.94% over the past 12 months, compared with -96.43% for ACTU (price return, excluding dividends). Past performance does not predict future results.

Are Actuate Therapeutics and Allarity Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons